BCG vaccine therapy for treatment of superficial bladder cancer.
A total of 42 patients were involved in the study of the effectiveness of BCG vaccine on superficial bladder tumours. The new Bulgarian vaccine CALGEVAX was administered intravesically in consecutive instillations once weekly and then once monthly for a period of 11 months. For intradermal application the F-70 subcellular preparation was used. On the grounds of their initial experience in the treatment of superficial bladder tumours with unspecific immunotherapy the authors would like to express their confidence in the effectiveness of the intravesical application of BCG vaccine.
Damianov
C
C
Department of Immunology, Research Institute of Infectious and Parasitic Disease, Sofia, Bulgaria.
Patrashkov
T
T
Tonchev
T
T
Engibarov
A
A
Kasabov
V
V
Chouchkova
M
M
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D006801:Humans; D007271:Injections, Intradermal; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine